Background: Multibiomarker blood tests have the potential to detect a broad range of cancer types and stages. In this study, we assessed the performance of a methylation and protein (MP) classifier using samples from a large, multicenter, prospectively collected case–control study. As part of the assay development process, we performed an exploratory analysis investigating the addition of a somatic mutation reflex approach (MP-reflex) on samples with scores below the threshold for a positive MP call but above a clear negative MP call. Methods: This study included 6,352 (1,438 cancer and 4,914 noncancer) samples representing all stages among 21 tumor organ types divided approximately equally between a training set and a test set. The sensitivity of the MP classifier was determined at a high specificity. The MP-reflex approach was investigated on MP samples at the same specificity threshold and detectable MP signals above prespecified lower thresholds. Results: Overall sensitivities for MP biomarkers were 50.9% (98.5% specificity), with sensitivities of 15.4%, 26.1%, 38%, 67.8%, 85.5%, and 37.5% for stages I, I and II combined, II, III, IV, and unknown, respectively. With breast and prostate cancers excluded, overall test sensitivities were 56.8%, with sensitivities of 17.2%, 30.7%, 48.6%, 73.5%, 86.5%, and 40% for stages I, I and II combined, II, III, IV, and unknown, respectively. Conclusions: MP biomarkers detected all solid cancers analyzed, including those without recommended screening and aggressive cancers with poor 5-year survival. Impact: These results demonstrate the potential clinical validity of multibiomarker testing for the detection of several cancer types.